Alzheimer’s Disease: More Than Just Memory Loss: An Awareness of the Disease and an Active Plan of Coping Strategies and Caregiving by Evans, Michelle Lynn
Gardner-Webb University
Digital Commons @ Gardner-Webb University
Undergraduate Honors Theses Honors Program
2016
Alzheimer’s Disease: More Than Just Memory
Loss: An Awareness of the Disease and an Active
Plan of Coping Strategies and Caregiving
Michelle Lynn Evans
Gardner-Webb University
Follow this and additional works at: https://digitalcommons.gardner-webb.edu/undergrad-honors
Part of the Medicine and Health Sciences Commons, and the Social and Behavioral Sciences
Commons
This Thesis is brought to you for free and open access by the Honors Program at Digital Commons @ Gardner-Webb University. It has been accepted
for inclusion in Undergraduate Honors Theses by an authorized administrator of Digital Commons @ Gardner-Webb University. For more
information, please see Copyright and Publishing Info.
Recommended Citation
Evans, Michelle Lynn, "Alzheimer’s Disease: More Than Just Memory Loss: An Awareness of the Disease and an Active Plan of Coping
Strategies and Caregiving" (2016). Undergraduate Honors Theses. 9.
https://digitalcommons.gardner-webb.edu/undergrad-honors/9
 
 
Alzheimer’s Disease: More Than Just Memory Loss 
 
An Awareness of the Disease and an Active  
Plan of Coping Strategies and Caregiving  
 
 
 
An Honors Thesis 
Presented to 
The University Honors Program 
Gardner-Webb University 
11 November 2016 
 
by 
 
Michelle Lynn Evans 
 
 
 
Accepted by the Honors Faculty 
 
 
 
 
 
 
 
 
________________________________ ________________________________________ 
Mr. Jay Zimmer, Thesis Advisor Dr. Tom Jones, Associate Dean, Univ. Honors 
     
________________________________  ________________________________________ 
Dr. Eddie Stepp, Honors Committee   Dr. Robert Bass, Honors Committee 
 
________________________________  ________________________________________     
Dr. Candice Rome, Honors Committee  Dr. Lorene Pagcaliwagan, Honors Committee   
 
 
 
 
 
 
 
Evans 1 
 
Acknowledgements 
I wish to thank my parents, Tony and Sherry Evans for supporting my education and giving 
me the opportunity to attend Gardner-Webb University. 
 
I also wish to thank my Thesis mentor and advisor, Mr. Jay Zimmer for giving me his 
guidance through this process and throughout my academic journey. 
 
I would also like to thank Dr. Tom Jones, Associate Dean of the Honors Program for 
providing me this opportunity to write a thesis and for making my love for this program 
grow. And thank you to the Honors Committee for the input and encouragement when 
writing my thesis.  
 
I would lastly like to thank PruittHealth of Elkin. Without my employment there, I would not 
have the experience of working with Alzheimer’s patients that sparked my idea of writing 
this thesis.  
 
 
 
 
 
 
 
 
 
 
 
Evans 2 
 
Abstract:  
Alzheimer’s Disease (AD) is a chronic neurodegenerative disease which 
leads to progressive mental deterioration that can occur in middle or old age. During 
the disease’s progression, various biochemical functions of the brain cells go astray 
and eventually lead to memory loss. What a lot of people do not always realize is the 
fact this disease goes beyond just losing memory. From my own observation as well 
as research studies, it has been noted that AD patients can experience sleep 
disruption, sundowning, speech decline, apraxia, agnosia, and behavioral changes 
such as depression and combativeness. As more of these signs and symptoms 
become evident to me, I conducted a plan as to how people who have loved ones 
with Alzheimer’s Disease can cope with them and those who experience the disease 
themselves can learn to improve everyday functions as the disease progresses. This 
thesis constitutes an awareness of all aspects of Alzheimer’s and a compilation of 
the best method for treatment and prevention.  
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Outline: 
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B. How to adjust to the AD lifestyle 
VI. Conclusion 
A. Summary of overall findings with suggestion of further research 
B. Awareness and a plan for treatment and prevention 
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I. INTRODUCTION 
One of the most commonly feared diseases in the world today is Alzheimer’s 
Disease (AD). Alzheimer’s is the most common form of dementia, which is a general 
condition that affects memory (“What is Alzheimer’s?” 2010). What makes dementia 
so devastating is the fact it is progressive. This means the symptoms will gradually 
worsen over time without any hope of improvement. But how quickly this progression 
occurs may vary with each person (Lipton and Marshall, 2013). One out of ten 
people will develop AD, and the majority of the people are ages 65 and older. Five 
percent of people with AD will have what is known as early onset Alzheimer’s, which 
often affects them during their 50’s or even 40’s (“What is Alzheimer’s?” 2010).  
Symptoms become worse over time as Alzheimer’s progresses and can 
become more evident at more advanced stages of the disease. The symptoms can 
be divided into two categories: cognitive and psychiatric (“About Alzheimer’s 
Disease,” 2016). A person with AD may live four to eight years after his or her 
diagnosis, but depending upon the person, some may even be able to live up to 20 
years longer. The later the stage of the disease, the more severe the outcome 
(“Stages of Alzheimer’s,” 2014).  
Alzheimer’s Disease is a chronic condition that affects the tissue of the brain. 
The brain consists of billions of nerve cells called neurons as well as dozens of 
neurotransmitters that travel and carry signals to other cells. The movement of these 
signals provide the basis of memories, thoughts, and emotions (“Brain Tour,” 2011). 
Over time, this disease leads to abnormal buildup of a protein known as beta-
amyloid that eventually forms plaques in between neurons. This protein comes from 
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a precursor protein that is found in the lipid membrane that covers neurons. These 
plaques interrupt signals from one cell to another (Colbert, 2013). Signals from cells 
travel through synapses, which are the spaces between the cells, that pass on 
information. This information is what enables people to carry out daily functions in 
their lives. Along with plaques, the proteins of normal brain tissue can misshape into 
fibers which then become tangled. Thus, the transporting of cell nutrients fails 
(Colbert, 2013). Nerve cell death is then inevitable, which leads to tissue loss 
throughout the brain. The brain shrinks dramatically, and this causes it to lose most 
of its functions. Figure 1 exhibits the changes of nerve cells and Figure 2 shows an 
illustration of a brain affected with AD compared to a healthy one. This shows the 
fact that Alzheimer’s is a disease of age. During the last stages, cell death can even 
occur in the part of the brain that regulates breathing as well as the heart. Therefore, 
Alzheimer’s disease is characterized as a timely death (“Brain Tour,” 2011).  
 
                                   
Figure 1: Comparison of Neurons Affected with AD versus Healthy Neurons. (“Brain 
Tour,” 2011). 
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Figure 2: Comparison of a Healthy Brain versus One affected with Alzheimer’s 
(“Brain Tour,” 2011).  
 
Studies have also shown defective autophagy is evident in the pathogenesis 
of Alzheimer’s. Autophagy is the degradative pathway for organelles and proteins 
and is vital for the survival of neurons (Nixon and Yang, 2011). It is a normal 
physiological process in the body that deals with the protein degradation and 
destruction of cells. It is also a major contributor of cellular homeostasis and 
metabolism (Heath and Xavier, 2009). When cells become awry or they become 
affected by a disease, autophagy kills the cells by a process known as apoptosis; 
programmed cell death. This process can also give the cells enough energy to 
enable continuous survival (Gump and Thorburn, 2011). Therefore, the failure of 
autophagy to properly degrade beta-amyloid proteins may be a contributing cause of 
Alzheimer’s Disease.  
As mentioned before, there are numerous people who develop Alzheimer’s 
Disease or at least know someone who does. This disease causes those to lose 
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memory to the point that they eventually forget major events or people in their lives. 
But what a lot of people do not realize is the fact that AD causes more than just 
memory loss. Dementia is a disease that affects memory, and although Alzheimer’s 
is a form of dementia, it is not defined by memory loss. It is defined as a disease that 
can affect daily living and progresses with age. It is the common assumption that the 
disease only affects memory that bewilders people when they see their loved ones 
not being able to speak, walk, or even become a completely different individual. 
Understanding all the aspects of Alzheimer’s and exactly what can happen to 
someone who develops this disease brings people one step closer to coping with it. 
 
 
II. COGNITIVE/INTELLECTUAL EFFECTS 
One of the cognitive effects of Alzheimer’s Disease is a decline in speech and 
language, such as aphasia. Aphasia is defined as the inability to communicate 
effectively (“About Alzheimer’s Disease,” 2016). Aphasia often involves language 
production or comprehension which may include speech, reading, and writing 
(Graham, 2008). The declining ability to speak and write is known as expressive 
aphasia whereas the inability to understand written or spoken words is known as 
receptive aphasia. Some individuals may even pretend to comprehend what 
someone is saying and just nod in agreement. This is called cover-up aphasia 
(“About Alzheimer’s Disease,” 2016). When an Alzheimer’s patient experiences any 
type of aphasia, this means their left part of the cerebrum, especially the temporal 
lobe, is most likely damaged by the disease. This part of the brain controls speech 
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and language (“Aphasia in Dementia,” 2007). The severity of aphasia in Alzheimer’s 
Disease patients is typically dependent upon the stage of the disease. During the 
early stages, one may have difficulty finding the right words to say with occasional 
semantic (meaning) substitutions (i.e., saying the word aunt instead of sister) but the 
speech may remain fluent as well as grammatically correct (Graham, 2008).  
As the disease progresses to the later stages, speech becomes less fluent 
along with the use of incorrect words and poor comprehension (Graham, 2008). 
Table 1 provides a summary of language impairments in Alzheimer’s within stages. 
Aphasia causes difficulties speaking or “getting the words out,” trouble finding words, 
understanding what others say, or with word semantics and naming familiar objects 
(“Aphasia in Dementia,” 2007). Some people who know someone with Alzheimer’s 
who may confuse what they think is a “memory problem” with what is actually an 
aphasia problem due to the common preconception that AD is a disease of memory 
loss. For example, some patients may forget the name of a word or its meaning such 
as asking “what is asparagus?” This indicates a loss of linguistic or semantic 
knowledge rather than memory (Graham, 2008). Aphasia can also become so 
severe that the individual may jumble words together where it just sounds like 
mumbling and his or her oral communication is completely lost. 
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Table 1: Summary of Language Impairments in Alzheimer’s Dementia 
 
(Graham, 2008). 
 
Along with a language decline, AD may cause other cognitive effects such as 
loss of physical function known as apraxia. Generally speaking, apraxia is a difficult 
symptom to live with because there is a disconnection between the idea of doing a 
task and the action of actually doing that task (Heltemes, 2015). It is a motor 
disorder that is caused by damage to the brain tissue due to a loss of nerve cells. 
The part of the brain that is affected is the posterior parietal cortex which plays an 
important role in planning movements. Before a certain movement can be initiated, 
the nervous system must know the position of body parts and the position of an 
object to be interacted with before movement occurs. Therefore, someone who has 
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Alzheimer’s Disease may have difficulty with the motor planning that is used to 
perform tasks or certain movements given that a command is understood as well as 
the willingness to perform the task (“Apraxia,” 2005). In other words, one will have 
the intent of doing the task as well as the muscle strength to do so, but will not 
receive the right brain messages to make it happen.  
An example of apraxia is a person who has strong fingers and can feel the 
buttons on his or her coat, but cannot figure out how to move his or her fingers in 
such a way to be able to button the coat. It is neither the finger sensation nor even 
the strength of their fingers that is the problem (Heltemes, 2015). Apraxia can also 
make a person do certain things out sequence or use an object incorrectly. For 
instance, they may use a toothbrush to comb their hair. They are using their arm in 
the motion to ‘comb’ but is using the wrong object to do so (“Apraxia,” 2005). Apraxia 
may also cause someone to not move his or her lips and tongue to the right place in 
order to say the correct sounds. Even though the muscles may not be weak, the 
messages from the brain to the mouth become disrupted. The amount of damage to 
the brain determines the severity of the apraxia. This is not to be confused with 
aphasia which is the inability to comprehend language (“Apraxia,” 2005).  
In the later stages of Alzheimer’s Disease, the motor skills that developed 
during childhood become affected. These skills include chewing, swallowing, and 
even walking (Heltemes, 2015). Apraxia is a type of disorder where one cannot 
execute voluntary movement despite the fact he or she may have adequate mobility, 
strength, sensation, coordination, and comprehension (“Apraxia,” 2005). There are 
several types of apraxia. Ideomotor apraxia is the deficiency in planning motor 
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actions that rely on semantic memory. Patients may be able to explain how to 
perform an action but are not able to act out the movement. Ideational or conceptual 
apraxia is the inability to conceptualize a task and the impaired ability to complete 
actions that require multiple steps. For example, these patients might put on shoes 
before they put on their socks. Buccofacial apraxia is the difficulty of carrying out 
movements of the face such as the inability to whistle or even smile to express 
emotions. Limb-kinetic apraxia is the inability to make precise movements of either 
the arm or leg (“Apraxia,” 2005). 
What surprises people when it comes to their loved ones affected with 
Alzheimer’s, is the fact that one day, they have the ability to move around without 
any problems to not being able to use their lower limbs to walk the next. Gait apraxia 
is a common explanation for some of the walking difficulties shown in patients who 
have AD. In a study from the Journal of Neurology, 60 patients with Alzheimer’s 
Disease who were free from other potential causes of walking deficits were selected. 
They were assessed with a new test evaluating the aspects of walking and related 
movements. Forty percent of the groups with Alzheimer’s performed below the cut 
off score, and half of them performed poorly (Sala, Spinnler, and Venneri, 2004). 
Performance in the Alzheimer’s group in the walking skills test positively correlated 
with the scores in a test that assessed gait apraxia with dementia severity. 
Therefore, this walking deficit is an independent and recognizable form of apraxia. 
Although there were several tests performed for this study, some of the walking 
movements that were tested for each patient include walking forward, walking 
backwards, walking while crossing legs over, and walking over an imaginary 
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obstacle. This study had shown that patients with AD have an increased risk of 
losing their balance and falling compared to those who do not have AD. This study 
also suggests that gait apraxia is a possible cause of bedridden patients not being 
able to turn over in their own bed (Sala, Spinnler, and Venneri, 2004). Therefore, 
they need to be turned by their caregivers every two hours.  
During the later stages of Alzheimer’s Disease, some may experience what is 
known as agnosia. This is the loss of the brain’s ability to interpret your senses 
accurately. In other words, it is the impairment of the ability to be able to receive or 
correctly understand information from the senses such as hearing, smell, taste, 
vision, and touch (Heerema, 2016).  
When it comes to vision, our eyes act like cameras as they transmit 
information for our brain to interpret. When someone has AD, the process of this 
interpretation becomes altered and the brain will no longer process the information in 
the same way even though the information that is being transmitted is the same in 
the eyes (Kelly, 2016). This impairment of visual input can result in the loss of the 
ability to recognize certain objects. Alzheimer’s does not cause any disorder in the 
eye, but it does cause severe damage in the areas of the brain that organize this 
visual information. Specifically, it causes damage to the occipital and temporal lobes 
which send and receive messages in the brain and the eyes (“About Dementia,” 
2006). There is a miscommunication between what the patient’s eyes see and how 
their brain interprets this image. Although they are able to see and describe the 
object, they are not able to tell someone what the object exactly is. The link between 
Evans 13 
 
a past experience with the object and the sight of the object has been lost (“About 
Dementia,” 2006).  
As the disease progresses, they also are unable to recognize loved ones. For 
example, they can see the face of a person but they cannot recognize the fact that it 
belongs to their spouse. They also may confuse their grandchildren as their children 
and may also not recognize their home, car, or even a beloved pet (Kelly, 2016). It is 
quite dangerous to believe that a person with Alzheimer’s who does not usually 
recognize family or friends, will somehow realize that they should not cross a certain 
path. It is also not a good idea to let people with AD who experience agnosia to 
drive. When they drive, they often drive the wrong way on a street, misread street 
signs, drive onto a highway using an exit ramp, inappropriately use the brake, or just 
drive abnormally (Kelly, 2016). 
The sense of smell can also be affected in Alzheimer’s patients. Some 
studies have shown this is due to the presence of beta-amyloid protein in the frontal 
lobe where the olfactory bulb is located. It consists of nerves that helps us detect 
and perceive odors. Research has also shown this is the area where the 
accumulation of the protein occurs first (Hereema, 2016). There was a study that 
reviewed the results of 130 autopsies with AD and found that there also was tau 
pathology. Tau proteins are the proteins that stabilize microtubules. The become 
twisted fibers which then start to accumulate in the brain cells. As Alzheimer’s 
Disease progresses, the ability to smell often decreases (Hereema, 2016).  
Agnosia can also affect the ability to understand the feeling of a full bladder 
(Hereema, 2016). This leads to incontinence. Therefore, most of the time, patients 
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are unable to recognize the need to use the restroom. Some other causes that lead 
to incontinence include forgetting where the restroom is located, not being able to 
walk, medications, and even stress (“Incontinence,” 2016). Not being able to sense 
the need to use the restroom causes someone with Alzheimer’s to lose control of his 
or her bladder and bowels. AD influenced incontinence can lead to other medical 
problems such as a urinary tract infection and bacterial infections of the digestive 
tract (“Incontinence,” 2016). Sometimes there are obstacles that may get in the way 
of the path to the restroom and clothing that is difficult to remove that can cause 
incontinence even when they can sense the need to go to the restroom.  
 
 
III. BEHAVIORAL/PSYCHOLOGICAL CHANGES 
People who develop Alzheimer’s Disease can experience changes other than 
cognitive and intellectual changes. Many tend to have behavioral as well as 
psychological problems. Most of the time, an individual with AD becomes somebody 
completely different than they were before by developing a change in personality.  
Research has shown that sleep disruption due to this disease may cause a 
change in behavior in patients. A research study from the journal Neurobiology of 
Aging explores a connection between sleep impairment and neurodegeneration. 
This conclusion was based on evidence that sleep disruption usually occurs before 
the onset of cognitive impairment (Kelly and Nadon, 2006). Scientists do not 
completely understand why this occurs in diseases such as dementia, but they do 
believe that these sleep changes result from the impact of Alzheimer’s Disease on 
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the brain.  There are a number of factors that could possibly contribute to sleep 
disturbances in Alzheimer’s. Examples include an agitation in the “internal body 
clock,” located in the hypothalamus, which then causes a biological mix-up between 
night and day and a falsely perceived less need for sleep (Bitwise, 1994).  
The research study investigated rapid eye movement sleep disruption and 
sleep fragmentation associated with cognitive impairment due to Alzheimer’s 
Disease. The aim of this study was to explore the dysregulation of the orexin system 
in AD pathology and how it relates to sleep deterioration in patients (Kelly and 
Nadon, 2006). Orexin-A is a neuropeptide produced by the hypothalamus. It 
regulates the sleep-wake cycle by increasing arousal levels and maintaining 
wakefulness. The purpose of this study was to measure cerebral spinal fluid (CSF)-
orexin levels in patients with AD based on the presence or absence of subjective 
sleep complaints compared to controls (no AD and no sleep problems). CSF 
samples were taken from each patient and then analyzed (Kelly and Nadon, 2006). 
The results showed significantly higher levels of CSF-orexin were detected in 
patients with Alzheimer’s Disease who have disruptions in their sleep-wake cycle 
compared to the controls. This study showed that the orexin system is affected early 
in AD progression. The patients with subjective sleep problems had higher CSF-
orexin levels compared to patients who did not have sleep problems and to controls 
who had similar sleep complaints. This suggests that the dysregulation of the orexin 
system may contribute to sleep impairment from AD pathology. This mainly affects 
REM sleep, as shown in figure 3, which can result in insomnia, prolong sleep 
latency, and nocturnal awakenings (Kelly and Nadon, 2006).  
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Figure 3: Negative correlation between CSF-orexin levels and REM sleep amount. 
Also shown is the linear regression fit across all patients (Kelly & Nadon).  
 
Some people with Alzheimer’s Disease have an increase in behavioral 
problems, such as agitation or confusion, in the late afternoon or early evening that 
can last throughout the night when the person is awake. This condition is known as 
“sundowning” (“About Dementia,” 2006). Some factors that may contribute to 
sundowning are end-of-day exhaustion—mentally and physically—and reduced 
amount of lighting, which can lead to seeing shadows causing patients with AD to 
misinterpret what they see and be confused and frightened. Other factors can 
include reactions to nonverbal cues of frustration, and disorientation caused by the 
inability to separate dreams from reality (Bitwise, 1994). 
Some of the symptoms that may appear in someone who experiences 
sundowning include repetitive speech, pacing, restlessness, wandering, 
disorientation of reality including time and place, agitation, and aggression toward 
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others (“About Dementia,” 2006). Sundowning affects about 25 percent of patients 
who are diagnosed with Alzheimer’s Disease. Sundowning is also called 
“sundowning syndrome” or “nocturnal delirium.” This term came about due to 
increased confusion, delusions, and paranoia. These symptoms typically appear 
when the sun goes down, but certain behaviors may also be experienced in the mid-
afternoon or early evening (Sharer, 2008).  
The phenomena of sundowning is a behavior that occurs spontaneously in 
AD patients. Some researchers say this sudden change in behavior could be due to 
environmental influences such as a change in shift of caregivers such as in a 
nursing home or things that simply agitate the patients. One research study has 
defined sundowning as “the appearance or exacerbation of behavioral disturbances 
associated with the afternoon and/or evening hours” (Volicer, Harper, Manning, 
Goldstein, & Satlin, 2001).  
Sundowning is associated with an increase in motor activities such as pacing, 
wandering, resistance to redirection, and an increased amount of verbal activity, 
especially yelling and name calling. The cause of sundowning is still unknown, but 
there are several theories that suggest influences that may explain this particular 
symptom of Alzheimer’s Disease (Sharer, 2008). One theory points to damage in the 
pineal gland that produces melatonin. Melatonin helps regulate our sleep/wake 
cycles, and reducing melatonin levels can cause irregular sleep patterns. Other 
theories include sleep apnea, hallucinations, delirium, fatigue, over-stimulation, and 
sensory deprivation. Another theory focuses on the energy levels of a person with 
AD. A person is most likely to get tired at the end of the day. This could make them 
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feel more anxious or stressed because this is the time of day when they are the 
busiest because they are coming home from work, cooking, cleaning, then going to 
bed. Since they are not able to do these things, it makes them feel even more 
agitated (“About Dementia,” 2006). One of the most popular theories suggest that an 
abnormality in the circadian rhythm will increases the likelihood of a patient to 
experience sundowning (Sharer, 2008).   
The circadian rhythm is influenced by the light and dark cycle (day and night) 
in the 24-hour period. A dysfunction in the circadian rhythm can result in an increase 
in behaviors such as sundowning. This could be due to the naturally produced 
melatonin declining due to increasing age or an abnormal regulation of core body 
temperature (Sharer, 2008). The research study, “Sundowning and Circadian 
Rhythms in Alzheimer’s Disease,” investigates the relationship between sundowning 
and characteristics of circadian rhythms in a group of patients with AD. Alzheimer’s 
Disease leads to pathological changes in the suprachiasmatic nucleus (SN) which 
causes a disruption in the circadian rhythms (Volicer, Harper, Manning, Goldstein, & 
Satlin, 2001). The study showed that 14 of the patients with AD sundowned never or 
rarely. Eight patients sometimes experienced it, and three patients usually did. 
Figure 4 shows that some of the patients who exhibited sundowning had increased 
locomotor activity in the evening but others had similar activity throughout the day. 
Patient one who usually has sundowning, had increased motor activity during the 
evening. Patient two who usually has sundowning, had the same motor activity 
throughout the day and therefore, this patient’s sleep schedule is irregular. Patient 
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three who never has sundowning compared to patient one, had less motor activity in 
the evening (Volicer, Harper, Manning, Goldstein, & Satlin, 2001). 
 
  
Figure 4: Distribution of Motor Activity During the Day and Night in Three 
Alzheimer’s Disease Patients With or Without Sundowning (Volicer, Harper, 
Manning, et. al). 
 
According to the results of the study, those with a sundowning status were 
significantly related to several circadian characteristics. The measurements of core 
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body temperature show that the patients with AD had a higher temperature and a 
greater acrophase (peak in the circadian cycle) than the comparison group who did 
not have AD. Figure 5 shows that the acrophase of motor activity occurred later in 
the patients who exhibited sundowning than in both the patients who did not exhibit 
sundowning and the comparison group. It also shows the acrophase of core body 
temperature occurred later in those who experience sundowning compared to those 
who experience sundowning less often (Volicer, Harper, Manning, Goldstein, & 
Satlin, 2001). 
 
 
Figure 5: Time of the Acrophases of Temperature and Motor Activity in Healthy 
Comparison Subjects and in Alzheimer’s Disease Patients With Sundowning 
Rarely/Never, Sometimes, or Usually (Volicer, Harper, Manning, et. al). 
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Higher amplitude of the circadian cycle of body temperature is possibly 
related to hypothalamic dysfunction, which is the area in the brain that controls the 
sleep/wake cycle. In this particular study, sundowning was present in 11 out of 25 
patients. It is reported that 13 percent of patients who experience sundowning is in a 
general nursing home population and 66 percent of patients with AD who live at 
home also experience this same symptom (Volicer, Harper, Manning, Goldstein, & 
Satlin, 2001). 
Depression is a very common behavioral change in someone who develops 
Alzheimer’s Disease especially during the early and middle stages. Some symptoms 
of depression in someone who has AD include apathy, loss of interest in activities, 
social withdrawing, isolation, trouble concentrating, and impaired thinking 
(“Depression and Alzheimer’s,” 2016). Some will even say that depression, to a 
certain point, could also be a risk factor of developing Alzheimer’s Disease. Most 
researchers believe depression plays a role as an early symptom in the 
neurodegenerative process of AD. Data also show neuropathological lesions in AD 
brains that correlate with the development of depressive behavior. These 
pathologies include reduced gray matter in the frontal and temporal lobes. These 
lesions found in the diseased brain are always accompanied by neuroinflammation 
(Lehman, 2011).  
Scientists have known for a long time that depression and dementia are 
linked. It was often the case that depression had to be ruled-out, including using a 
trial of antidepressants, before dementia could even be diagnosed. But now they say 
that depression can exist together with Alzheimer’s (“About Dementia,” 2006). The 
Evans 22 
 
cognitive impairment that people with AD experience often makes it difficult for them 
to articulate their sadness, hopelessness, guilt other types of feelings that are 
associated with depression. This is why depression in Alzheimer’s does not always 
look like depression in people without the disease. Depression in AD is usually less 
severe, may not last as long and the symptoms may come and go, and the person 
may be less likely to talk about or attempt suicide (“Depression and Alzheimer’s,” 
2016).  
There seem to be two ways depression and Alzheimer’s Disease are linked 
together. One way is the fact that for some people, the diagnosis of this disease is 
enough to trigger the depression, and the other way is the fact that the disease 
appears to affect the chemicals released by neurons in the brain that give signals. 
Even just damage to brain tissue can cause depression (“About Dementia,” 2006). 
For patients to be diagnosed with depression in Alzheimer’s, they must have either a 
depressed mood, or a decreased pleasure of usual activities along with social 
isolation, loss of appetite that is not from some other medical cause, disruption in 
sleep, slowed behavior, irritability, loss of energy, feelings of worthlessness, or 
recurrent thoughts of death (“Depression and Alzheimer’s,” 2016).  
Another type of behavioral change that could possibly be associated with 
Alzheimer’s Disease is anger and aggressive behavior; verbally and physically. This 
aggressive behavior can either occur suddenly with no apparent reason, or can 
occur from a frustrating situation (“Aggression and Anger,” 2016). This 
neuropsychiatric symptom (NPS) is strongly associated with caregiver distress which 
can lower the patient’s quality of life. If the caregiver does not give them the 
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adequate care they need, this can affect the patients and their aggressive behavior. 
This also increases the likelihood of being institutionalized in an Alzheimer’s unit or a 
nursing home. Many patients are aggressive toward others, including their 
caregivers, and can pose a threat of danger to themselves, and this behavior can 
increase over time with this disease. In a small study of patients with AD, aggressive 
behavior occurred in 42 percent of patients and had increased to 75 percent of 
patients in a 24-month observation. Although some of these behaviors are 
situational and can be managed, about half are unpredictable (Dennehy, Kahle-
Wrobleski, Sarsour, & Milton, 2013).  
Physical and verbal aggression can be caused by many factors including 
physical discomfort, environmental factors (overstimulation of loud noises), and poor 
communication (“Aggression and Anger,” 2016). One of the major concerns of 
Alzheimer’s Disease is combativeness. This aggression has nothing to do with his or 
her personality, rather it is just a common symptom of this disease. As the illness 
progresses, a patient develops less and less tolerance for frustration, and the 
disease usually affects the part of the brain that controls inhibition. When this 
happens, there is no barrier between thoughts and action. Therefore, thoughts 
become alive without the benefit of the brain to tell the patients when they do 
something wrong. There could be consequences or they could hurt someone 
(“Understanding Combative Behavior,” 2016). Combative behavior can be stimulated 
by different reasons such as boredom, medications with negative side effects, 
depression, too much activity, physical pain, fatigue, other medical problems (ex. 
urinary tract infection), unkindness, and protection from intrusion (ex. bathing). 
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Although it is hard to cope with, being aware of why such behavioral issues occur in 
patients with Alzheimer’s Disease and understanding why they cannot help the 
things they do, can actually help those who are facing it.  
 
 
IV. MEDICAL TREATMENTS 
There is no cure for Alzheimer’s Disease, but there are ways in which it can 
be treated. There have been several clinical trials to discover types of drugs that will 
slow the progression of the disease in some people or temporarily alleviate the 
symptoms that accompany it.  
An example of a type of medication used for this disease is a group of the 
same chemical called cholinesterase inhibitors, short for acetylcholinesterase. One 
example is donepezil. In a brain of a person who has AD, there are lower levels of 
acetylcholine which is a chemical that helps to send messages between nerve cells. 
When one has Alzheimer’s, there is also a loss of nerve cells that use this 
acetylcholine. These declining levels of acetylcholine and the progressive loss of 
nerve cells are linked to the worsening of AD symptoms (Kelly, Harvey, & Cayton, 
1997). Donepezil alleviates effects on cognition (memory and concentration) and 
neuropsychiatric symptoms as well as with daily living activities (ex. personal care 
and dressing) because it prevents the enzyme acetylcholinesterase from breaking 
down acetylcholine in the brain. This increase of acetylcholine leads to an increase 
amount of communication between nerve cells which helps stabilize the symptoms 
in Alzheimer’s Disease (Conti et. al, 2016).  
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Donepezil is mainly offered to those who have mild to moderate Alzheimer’s, 
but there is also strong evidence that it helps those in the severe stage of the 
disease. It is shown that 40 to 70 percent of people benefit from taking medication 
involving a cholinesterase inhibitor. Symptoms would improve temporarily, such as 
in between six and twelve months, and then gradually worsen over the following 
months (Kelly, Harvey, & Cayton, 1997).  
In a research study from European Journal of Clinical Pharmacology, it is 
hypothesized that donepezil could be linked to a neuroprotective effect that leads to 
a reduction in toxic beta amyloid fibrils which is a real anti-pathogenic effect. It has 
also shown to regulate the immune system response. In this case, the inflammatory 
phenomenon involved with the pathogenesis of AD (Conti et. al, 2016).  
Memantine is another cholinesterase inhibitor, but it has a different pathway 
than donepezil. It protects brain cells by blocking the effects of glutamate, which is 
another chemical that helps send messages between nerve cells. Glutamate is 
released in an excessive amount when brain cells are damaged by Alzheimer’s 
Disease, and the release of this chemical causes the brain cells to be damaged 
even further (Kelly, Harvey, & Cayton, 1997). Memantine has been approved to treat 
patients with AD at the moderate to severe stages of the disease. This type of drug 
is known as a noncompetitive glutamatergic NMDA receptor antagonist. To go in 
further about its treatment pathway, it attenuates phosphorylation of tau through a 
decrease in glycogen synthase kinase-3beta activity (Wang, Blanchard, Grundke-
Iqbal, & Iqbal, 2015). It has shown to slow down the progression of symptoms 
including disorientation and the difficulties of carrying out daily living activities. There 
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is also some evidence that it can help with delusions, aggression, as well as 
agitation (Kelly, Harvey, & Cayton, 1997).  
Although drug treatments for those who have Alzheimer’s Disease are very 
important when it comes to the biological aspects of the disease, it only delays the 
symptoms rather than gets rid of the disease altogether. This type of treatment 
should be only one part of the patient’s overall care. There are other ways to treat 
these people that are just as important when it comes to helping someone live well 
with Alzheimer’s.  
 
 
V. A PLAN TO CARE 
Alzheimer’s Disease is not only known in the United States. This disease is 
common throughout the world. But this does not mean AD is treated the same in 
every country. Some countries, such as India, view people with Alzheimer’s as 
mentally insane or just simply inhuman. Rather than treating them, they are locked 
away in one place without any interaction with anyone and without proper care. They 
lose their respect and dignity this way. 
From research and my own experience, the best treatment for someone with 
Alzheimer’s Disease is to care for them. Caring for them shows compassion and 
does not just make them a scientific experiment. It is important to make people 
realize that they are still people and that they had a life before the disease took it 
away. It is our job as caregivers or family members who know someone with this 
disease to care for them and improve their quality of life. We treat the person rather 
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than the disease, and this is the best medicine we can give them. Holistic treatment 
is more effective than medicine. Caring and providing for AD patients treats them 
from the inside and as a whole, whereas medicine just delays the symptoms. The 
symptoms will come and go with medical treatment, but helping them live their life 
will give them a chance to keep their humanity. Therefore, we need a plan. A plan to 
care.  
Starting with Cognitive symptoms that a lot of AD patients develop, there is a 
lot we can do to help. I have come around those who have expressive aphasia to the 
point where I could not understand them and those who just cannot understand what 
I am telling them. It is important to assume that they are always listening and check 
their understanding with yes/no questions. Using sentences that are short and to the 
point can help them understand things a lot better as well as keeping the noise 
volume to a minimum. Standing where they can fully see you is also a way to keep 
their focus and understanding what they are being told. It is always important to 
remember that the patient is an adult and we need to let them make their own 
decisions and keep them in the conversation. Even though it’s hard for them to do 
so, they still have a right to not let people make decisions for them. A caregiver or a 
family member should be patient with their aphasia and to give them the time they 
need to try to speak and get their point across for it respects their dignity (“Aphasia 
in Dementia,” 2007). It would make it harder for a patient to participate in 
conversation if one is becoming frustrated and agitated toward them. Understanding 
their difficulty in conversation and speech is the first step to helping them. 
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People can also help someone with AD who experiences apraxia, like 
mentioned earlier, this is a disconnection between messages sent from the brain 
and movements with objects or in general. Here are some ways in which someone 
can care for those who have this problem with this disease. Using modeling to help 
the patient get through a task or guiding your hands over theirs can make them more 
aware and understand what they need to do to get the job done. For example, if they 
are having trouble buttoning their shirt, you can show them how to button it, and then 
have him or her try to do it themselves. Or if they cannot position themselves in a 
chair correctly, you can put your arms around them and guide their body to align to a 
chair. Even demonstrating how to chew can help them be able to chew in the later 
stages (“Apraxia,” 2005). Caregiving for those who cannot walk because of AD can 
be harder to cope with them, but just being patient with them and helping them get to 
locations they desire to be is just enough to care for them for they are not able to do 
a lot on their own. Since people with Alzheimer’s can easily confuse objects with 
other objects. Putting similar looking items hidden away from commonly used places 
like the bathroom or kitchen can even keep them from dangerous situations. For 
example, one can hide things that might look like a tube of toothpaste that might be 
used by accident such as ointments or denture adhesives. One can also set out the 
‘correct’ item for a task to make things much easier such as setting out only a spoon 
when they are about to eat a bowl of soup. One can also set out items in the proper 
sequence for those who are more likely to do something in an improper way. For 
instance, setting out clothes to dress in, one can stack them with the underclothing 
on top, shirt and pants in the middle, and socks at the bottom (“Apraxia,” 2005). With 
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a better understanding of what happens to an AD patient with apraxia, caregivers 
can better prepare for it, manage it, and eliminate frustrations that it might cause for 
both the patient and the caregiver.  
It is important to be supportive of someone who has Alzheimer’s Disease, 
especially if they are unable to understand their senses because of the damage that 
occurs there which keeps them from being able to see well, hear, or even use the 
bathroom. You can reassure the patient in order to reduce feelings of uselessness or 
embarrassment. You can say that everything is just fine instead of pointing out their 
mistakes. Do not scold the person if they do make a mistake or make them feel 
guilty. It is also very important to respect their need for privacy. Otherwise, we are 
just dehumanizing them and not maintaining their dignity. Doing things for their 
incontinence can also help them, for they cannot control it if they do not feel the 
need to go to the bathroom anymore. You can make it easier for them to find the 
bathroom. But withholding fluids can cause dehydration and lead to a urinary tract 
infection and increased agitated behavior (“Incontinence,” 2016).  
Caring for patients with Alzheimer’s Disease who experience behavioral 
changes can make a difference to improve their life and cope with the disease. Not 
every patient with AD experiences sleep issues or sundowning, but there are ways 
in which one can deal with these symptoms as well. If a patient is awake or upset, 
approach them in a calm manner and find out if they are needing something. They 
should be gently reminded of what the time is and avoid arguing by reassuring them 
that everything is all right, especially if they are confused. Do not use physical 
restraint if they get up and start wondering off, it will only agitate them. Instead, allow 
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them to continue to pace under your supervision (Bitwise, 1994). If they are at home, 
make sure it is well lit in the evening which will reduce their dark surroundings. Make 
a comfortable and safe sleep environment as well such as keeping doors and 
windows locked and providing a comfortable temperature. It is also important to 
maintain a sleeping schedule to allow for a more restful sleep at night and avoid 
stimulants such as sweets and caffeine that can keep them up at night. Discouraging 
afternoon napping and planning more activities such as trips and bathing in the 
morning or early afternoon will make them less likely to be awake at night. Even 
limiting environmental distractions that occur during the evening can help them 
maintain a proper sleep schedule (Bitwise, 1994).  
When a patient with Alzheimer’s experiences depression, it can be hard for 
them to get back to where their life used to be, but getting the appropriate treatment 
for depression can significantly improve their quality of life. The best kind of 
treatment for depression in AD involves some medication, counseling, and a gradual 
reconnection to activities and people that have always brought them happiness. 
Telling them to “try harder” or to “cheer up” is not helping anything. Those with 
depression are hardly able to make themselves better without will. What makes 
them better is lots of support, reassurance, and professional help. Support groups 
can be very helpful, especially to those who are in the early stage for Alzheimer’s so 
that they can become aware of their diagnosis and take on an active role of seeking 
help from others. Scheduling a routine, and making a list of activities that they fully 
enjoy can also help in overcoming their depression. Celebrated small successes and 
occasions such as their birthday can even improve their behavior and make them 
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feel very important. Family members can provide reassurance that the patient is 
loved, respected, and appreciated as part of the family, and not just to feel sorry for 
them for what limited things they can do now. They need to be reassured that they 
will not be abandoned (“Depression and Alzheimer’s,” 2016).  
Coping with someone who has AD with aggression and anger can be one of 
the hardest things to do, and I have experienced this type of frustration. I have been 
hit and yelled at, but it is very important to understand that they cannot help what 
they do. It is hard for them in fact to think before doing something because of the 
way their brain has disconnections between signals. When a patient is becoming 
angry and aggressive, it is important to identify the immediate cause of the 
aggression, such as thinking about what happened right before the reaction that may 
have triggered this sudden behavior. Many caregivers may not realize that pain can 
actually cause a person with AD to act aggressively, so one must rule out pain as a 
source of stress. It is vital to focus on the patient’s emotions rather than the specific 
facts. In other words, look for the feelings behind the actions or words. Getting upset 
with a patient can make him or her even more aggressive so that is not the answer. 
Being positive and reassuring will help as well as speaking in a soft tone. Limiting 
distractions and trying a relaxing activity can help them become more calm. And as 
mentioned before, it is not good to use force and restraint unless the situation is very 
serious for they can become even more frustrated and even cause personal harm 
(“Aggression and Anger,” 2016).  
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VI. CONCLUSION 
Alzheimer’s Disease is a progressive and fatal disease that so many 
individuals develop in their later stages in life. One out of ten people are affected 
with this disease over the age of 65 (“What is Alzheimer’s?” 2010). No one is 
immune to this disease because it comes gradually with the abnormal buildup of 
protein that later forms into plaques and tangles that kills brain cells. The disease 
starts with memory loss and worsens over time. It is the common assumption that 
Alzheimer’s Disease is only about memory loss, but this disease in fact, is 
associated with a lot more; it takes over your life. We take for granted simple 
recollections that happened a few days ago or even years ago that we remember. 
Those with AD have more trouble remembering just what happened a few minutes 
ago (“Brain Tour,” 2011).  
Although memory is affected significantly by this disease, it is not the only 
consequence. After affecting memory, more plaques and tangles spread to different 
regions in the brain which kills even more cells and eliminates specific functions 
which is also known to be the different stages of Alzheimer’s. These different parts 
of the brain being affected by this disease lead to speech decline and language 
incomprehension, physical dysfunction, senses to not be accurately perceived, a 
disruption in the sleep/wake cycle, depression, and losing control over emotions and 
feelings and turning towards aggression. It can even lead to affecting the part of the 
brain that regulates breathing and the heart which means Alzheimer’s is a disease of 
a timely death.  
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There are risks when it comes to developing AD. Alzheimer’s Disease is a 
disease of aging which is the strongest risk factor. The older a person gets, the more 
likely he or she is to develop it. Genetics can also be a factor. Those who have one 
or more family members with AD are more likely to develop it than those without a 
family history of it. Studies have discovered the fact that women are at greater risk 
for this disease than men (Braunstein, 2010). Strong evidence has also shown a link 
between brain health and heart health. The brain is nourished by a rich network of 
blood vessels. A heartbeat pumps about 25 percent of blood to the brain, and the 
brain cells use about 20 percent of the nutrients and oxygen that the blood carries. 
Therefore, an unhealthy heart could lead to an unhealthy brain. Evidence has 
pointed stress can be a contributor to AD as well whether it is mental stress, a 
certain lifestyle, or some sort of head trauma (Braunstein, 2010). 
 Despite these risk factors, there are ways in which people can prevent the 
development of Alzheimer’s Disease and maintain the function of their brain. 
Maintaining good health starts with your brain. The brain requires a lot of care. It is 
the most vital organ in the human body. Without it, you cannot move, speak, or even 
breathe. It makes sense that whatever is good for the heart is good for the brain, so 
doing something everyday to prevent heart disease, high blood pressure, and even 
diabetes can help (Braunstein, 2010). Eating less fat in your diet and eating more 
foods that are rich in antioxidants can feed your brain and give it the proper nutrients 
it needs. Even keeping your brain active and engaged can increase its vitality and 
preserve brain cells and functions. Playing games, learning new things, and daily 
crossword puzzles can stimulate the brain. Physical exercise can also help prevent 
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AD as it regenerates blood cells. Studies has shown that regular exercise can 
improve memory and cognition (Braunstein, 2010). 
The disease’s progression takes place on average of eight to ten years 
(“Stages of Alzheimer’s,” 2006). What people need to realize is that the disease is 
relentless and for right now, is incurable. The brain is the most complex organ in the 
human body, and scientists are still unsure of the exact cause of Alzheimer’s. 
Further research is suggested to evaluate what exactly happens when the brain 
goes awry and the effects of this disease. Further research could also discover how 
patients can become fully treated to improve their life when fighting this progressive 
disease.  
 Treating someone with AD requires an active plan that does not just mean 
medically. Alzheimer’s is not defined as losing memory; it is defined as a disease 
that affects one’s lifestyle and daily functions. There is a fine line between treating 
memory loss and other symptoms, and treating someone’s ability to live. Helping 
people to understand Alzheimer’s Disease will reduce the stigma of this disorder, 
improve care, and even help to find a cure. Doing your part, especially if having a 
family member or a loved one who has the disease, to care for them and get them 
the appropriate help they need is the first step in improving their life. This is the best 
treatment patients can receive in fighting Alzheimer’s Disease.  
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